Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 20643572)

1.

Antibody-drug conjugates: targeted drug delivery for cancer.

Alley SC, Okeley NM, Senter PD.

Curr Opin Chem Biol. 2010 Aug;14(4):529-37. doi: 10.1016/j.cbpa.2010.06.170. Epub 2010 Jul 17. Review.

PMID:
20643572
2.

Potent antibody drug conjugates for cancer therapy.

Senter PD.

Curr Opin Chem Biol. 2009 Jun;13(3):235-44. doi: 10.1016/j.cbpa.2009.03.023. Epub 2009 May 4. Review.

PMID:
19414278
3.

[Antibody-drug conjugates: a new therapeutic class?].

Chofflon I, Dietrich PY, Thang NN.

Rev Med Suisse. 2013 May 22;9(387):1080-2, 1084-6. French.

PMID:
23757915
4.

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Senter PD, Sievers EL.

Nat Biotechnol. 2012 Jul 10;30(7):631-7. doi: 10.1038/nbt.2289.

PMID:
22781692
5.

Linked-in: design and efficacy of antibody drug conjugates in oncology.

Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK.

Oncotarget. 2013 Mar;4(3):397-412.

6.

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.

Fanale MA, Younes A.

Drugs. 2007;67(3):333-50. Review.

PMID:
17335294
7.

Antibody-drug conjugates in cancer therapy.

Sievers EL, Senter PD.

Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823. Epub 2012 Oct 3. Review.

PMID:
23043493
8.

Antibody-drug conjugate technology development for hematologic disorders.

Bander NH, Czuczman MS, Younes A.

Clin Adv Hematol Oncol. 2012 Aug;10(8 Suppl 10):1-16.

PMID:
23072775
9.

Targeted cancer therapy: conferring specificity to cytotoxic drugs.

Chari RV.

Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. Review.

PMID:
17705444
10.

Investigational antibody-drug conjugates for hematological malignancies.

Polson AG, Ho WY, Ramakrishnan V.

Expert Opin Investig Drugs. 2011 Jan;20(1):75-85. doi: 10.1517/13543784.2011.539557. Epub 2010 Dec 11. Review.

PMID:
21142808
11.

Anti-CD30 Antibodies for Hodgkin lymphoma.

Foyil KV, Bartlett NL.

Curr Hematol Malig Rep. 2010 Jul;5(3):140-7. doi: 10.1007/s11899-010-0053-y. Review.

PMID:
20446121
12.

World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.

Beck A, Senter P, Chari R.

MAbs. 2011 Jul-Aug;3(4):331-7. Epub 2011 Jul 1.

13.

The next generation of antibody drug conjugates.

Mack F, Ritchie M, Sapra P.

Semin Oncol. 2014 Oct;41(5):637-52. doi: 10.1053/j.seminoncol.2014.08.001. Epub 2014 Aug 12. Review.

PMID:
25440608
14.

Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.

Brumlik MJ, Daniel BJ, Waehler R, Curiel DT, Giles FJ, Curiel TJ.

Expert Opin Drug Deliv. 2008 Jan;5(1):87-103. Review.

PMID:
18095930
15.

Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.

Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M, Sauk JJ.

J Drug Target. 2005 Apr;13(3):189-97.

PMID:
16036307
16.

Tumor targeting using anti-her2 immunoliposomes.

Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, Nielsen UB, Marks JD, Papahadjopoulos D, Benz CC.

J Control Release. 2001 Jul 6;74(1-3):95-113.

PMID:
11489487
17.

Integrin targeted drug and gene delivery.

Wang Z, Chui WK, Ho PC.

Expert Opin Drug Deliv. 2010 Feb;7(2):159-71. doi: 10.1517/17425240903468696. Review.

PMID:
20095940
18.

Anticancer carrier-linked prodrugs in clinical trials.

Kratz F, Abu Ajaj K, Warnecke A.

Expert Opin Investig Drugs. 2007 Jul;16(7):1037-58. Review.

PMID:
17594188
19.

Nanoparticles for drug delivery in cancer treatment.

Haley B, Frenkel E.

Urol Oncol. 2008 Jan-Feb;26(1):57-64. doi: 10.1016/j.urolonc.2007.03.015. Review.

PMID:
18190833
20.

Drug-conjugated antibodies for the treatment of cancer.

Lambert JM.

Br J Clin Pharmacol. 2013 Aug;76(2):248-62. doi: 10.1111/bcp.12044. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk